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FROM 
THE EDITOR
Science & the Supernatural
    As a child, I remember creeping downstairs in the mid-
dle of the night to get a glass of water. Turning around, I 
felt as if there was something in the dark behind me. I’d 
start walking faster and faster until my walk turned into 
a desperate sprint, sighing with relief when I reached my 
parent’s room. As an adult, I know that my childhood fears 
of the dark were irrational and probably magnified due 
to my obsession with the Goosebumps series. Nowadays, 
my fears seem to be more rational like the fear of falling 
from great heights or of poisonous creatures. After all, 
the history of evolution has taught us that fear is a selec-
tive advantage that keeps us away from danger. But why is 
it that I still jump at something as harmless as clowns in 
a horror movie or the sound of my floorboards creaking? 
    Our cover story hopes to bring you some thoughtful dis-
cussion as to why humans fear unexplained phenomenon 
like ghosts and the paranormal. In “The Evolution of Fear” 
undergraduate Alisha Ahmed relates the physiological and 
neural basis of the fear response to broader implications 
like its role in anthropological and religious history. Al-
though the study of such an abstract idea may attract skep-
tics, there are some significant implications that come with 
this, ranging from increased understanding of mental dis-
orders to new fronts in national security. I hope you enjoy 
learning about this topic as much as I did. Turn to page 14.
     We are incredibly happy to share the tremendous amount 
of work put into each of the features of our inaugural issue by 
our writers, editors, designers, and managerial staff. The late 
night writer-editor meetings, designer sessions, email corre-
spondences, and long hours put into making the content were 
well worth the effort to bring you this issue. As the roots of 
The Triple Helix spread through the Austin community, we 
hope the ideas in these articles inspire you to develop opin-
ions of your own and to share your stories with the world.
About Us
The Triple Helix at UT Austin is an interdisciplinary journal committed to bridging the gap between science, ethics, and 
society. We aim to explore the intricate moral, socioeconomic, and environmental ramifications of an increasingly sci-
ence-driven world while highlighting the ways that science affects our ideas of humanity. Covering subject matter ranging 
from technology to law and business to biology, we provide a forum to discuss issues in society from multiple perspectives . 
Staffed by a diverse group of writers, editors, and graphic designers, the Triple Helix strives to promote an interdisciplinary 
mindset for people of all backgrounds, with the hope of encouraging readers to ask questions and gain new perspectives. 
We are proud to showcase our Fall 2018 publication, a collection of articles and ideas designed, written, and edited by stu-
dents here, at The University of Texas at Austin. We hope you enjoy!
Vishal Patel is editor in chief of The Triple Helix, 
connect with him at TexasTTH@gmail.com.
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Politics of 
Grant Writing     
Scientists and researchers are at the mercy of the personal 
opinions of those in political power, as they hold the ultimate 
key to success: money. Funding permeates every aspect of a 
researcher’s life, from hiring graduate students to attending 
conferences and buying chemicals. The vast majority of sci-
entific research is funded by governmental institutions such 
as the National Science Foundation, National 
Institutes of Health, and the Defense 
Advanced Research Projects Agency. 
Grant writing accounts for approx-
imately 40% of time spent at work by 
tenured faculty, encompassing late 
nights and weekends, especially for 
younger professors. In fact, some 
grants even have a net negative val-
ue- they take away valuable time 
that applicants and peer review-
ers could use to teach, attend 
conferences, and do research.
The already labyrinthine sys-
tem of scientific funding and 
grant writing is exacerbated by 
the political nature of govern-
mental organizations and the 
impact of the personal views of 
those in power. Even more so, 
the nature of the governmental 
landscape can be detrimental to 
the progress of science and technology. 
     Research topics can often induce powerful 
and polarizing opinions, especially in biological 
and genetic engineering disciplines. For example, “fetal 
tissue research” is a term thrown around in Congress and a 
topic of great controversy. A handful of Planned Parenthood 
clinics in two states supply fetal tissue for medical research 
and came under fire in 2015 when covertly filmed videos of 
physicians discussing fetal organs for research were released. 
Most of the NIH projects utilizing fetal tissue study infectious 
diseases, specifically HIV/AIDS, and developmental biology. 
Researchers who oppose these methods claim that other mod-
el systems and techniques can be used, while those involved 
champion the idea that fetal tissue cannot be replaced as an 
experimental model. Regardless of the claims posed by 
either side, the real question remains how much power 
our modern-day scientific patrons have over the men and 
women who pursue scientific discovery. The patrons who 
control the allocation of fiscal resources to research insti-
tutions inevitably impact the scientifics topics pursued. 
     While controversial topics receive more public atten-
tion and captivate the desks of lawmakers for longer pe-
riods of time, day to day research is also at the mercy of 
the government. Transitions of power and policy modi-
fications can sway scientific research in a myriad of ways. 
President Trump’s first budget request to Congress in 
early 2017 called for a six billion dollar cut to NIH 
funding and a surge in nuclear weapons fund-
ing, a 20% decrease from the year before. This 
would bring the budget back to the lowest 
level in 15 years, a time frame unimag-
inable in the constantly evolving 
field of research. The Associ-
ation of American Med-
ical Colleges said the 
cuts would “crip-
ple the nation’s 
a b i l i t y to support and 
deliver” biomedical re-
search. Eastern countries 
such as China, Korea, and 
India have started to pour 
more money into their re-
search programs and public 
universities, and cuts to Amer-
ican research leave us at risk of 
getting left behind in the dust. 
      
As a country, we must come to-
gether to move forward. Our people have al-
ways been our strength, and our commitment to scien-
tific research is imperative in this ever-changing world. 
A bright future awaits, and we must approach it with 
open arms. Let’s keep asking these difficult questions, 
encourage our children to think differently and push 
the horizon, and hold our government accountable. The 
future is what we make it, and change starts with us. 
Article by Kavya Rajesh
Graphic Design by Josh Goh 
SCIENCE
AGENDA
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HIV: Path to A Cure
In June 1981, the Center for Disease Control (CDC) reported the first cases of autoimmune deficiency syn-drome (AIDS) in the United States in five previously 
healthy young men.1 Research over the next couple of years 
uncovered the presence of a virus, the human immunodefi-
ciency virus (HIV), as responsible for this growing epidem-
ic. HIV was shown to preferentially infect specific white 
blood cells, known as CD4+ T helper cells. Throughout the 
1980’s and 1990’s while the epidemic was expanding, only 
a few medical treatments were available. Without treat-
ment, those infected with HIV inevitably developed AIDS. 
In 1997, the FDA approved combination antiretrovi-
ral therapy for treating HIV. This revolutionary new ther-
apy combined a variety of pharmaceutical drugs that tar-
geted the virus at various stages of its life cycle. Despite 
some side effects, the drugs effectively stopped the virus 
from replicating, and a standard blood test could no lon-
ger detect HIV. These results were so promising that sci-
entists and physicians thought that only a few years of the 
medication could completely cure someone of HIV. Un-
fortunately, this enthusiasm was premature. Since HIV has 
the remarkable ability to insert its own viral genome into 
the human genome of the cell it infects, the only way to 
completely eliminate it is for host cell to die. Much to the 
dismay of doctors and patients alike, when antiretroviral 
treatment was stopped, the viral load quickly rebounded 
to high levels. Small amounts of dormant virus persist in 
immune cells known as resting memory CD4+ T cells. In 
this dormant state, the virus does not reproduce within the 
cellular host. Circulating immune cells, which would nor-
mally kill virally infected cells, completely ignore these cells 
since they appear to be healthy. Thus, people who are infect-
ed with HIV must remain on antiretroviral treatment for 
their entire lives, taking a daily pill to keep the virus at bay. 
The question then became, how can we eliminate this 
dormant virus? Unfortunately, the cells that harbor the vi-
rus are very long-lived cells. Research has predicted that 
for these cells to die on their own (and take the virus with 
them), it would take over 70 years of continuous treatment.2,3 
Since this is not a practical strategy, the HIV research field 
has taken multiple approaches to cure HIV by aiming to 
eliminate the dormant virus. The most heavily researched 
approach is known as the “shock and kill” strategy. This 
strategy seeks to “shock” the dormant virus “on” so that 
it can be detected and “killed” by our immune system, 
as normally occurs when our body detect foreign invad-
ers. Importantly, people remain on antiretroviral med-
ication to block the virus from infecting new cells, so 
any virus produced from this strategy is not harmful. 
There have been multiple small-scale clinical trials us-
ing this approach with mixed results. Although drugs 
have been shown to successfully “shock” the virus out 
of its dormant state, the infected cells were not elimi-
nated.4-8 Further research is ongoing to increase the ef-
fectiveness of the “kill” aspect of the immune system by 
pairing the “shock” with a vaccine to stimulate the im-
mune system to kill infected cells. In one recent study, 
participants received a drug called romidepsin, which 
was used to “shock” the virus in tandem with a T-cell 
vaccine to help boost the immune system to eliminate 
infected cells. Here,  the virus was reactivated by ro-
midepsin and a modest number of infected cells were 
also eliminated.9 Current studies are applying a similar 
approach and hopefully these advancements will make 
this an effective strategy moving forward. 
Over the past three decades HIV treatment has 
come a long way, from a once terminal disease to one 
that is now treatable with medication. With advance-
ments in scientific research, hopefully one day HIV 
will enter the realm of becoming a curable disease.
*Check our site for citations.
FROM THE 
EXPERTSArticle by Katherine Bruner, PhD (left) & Nina Hosmane, PhD (right)
Graphic Design by Zane Shah
Forget your monthly trip to the pharmacist: In the near future, you may be able to produce drugs from the comfort of your own home. On August 3rd, 2015, a major breakthrough in attaining this reality occurred when the FDA approved Spritam (levetiracetam), an orally-ingested tab-
let used to treat partial onset, myoclonic, and generalized tonic-clonic seizures in children and adults 
with epilepsy.1 Beyond Spritam, barbiturates, calcium channel moderators, and approximately thirty 
other varieties of pharmaceutical drugs treat seizures as well. In fact, Spritam is not even the only com-
mercial variant of levetiracetam, its generic name.2 What separates Spritam from its competitors is not 
a unique chemical composition, but the endless potential behind its production method: 3D printing. 
     Currently, orally-ingested drugs are produced by 
power-blending chemicals, crushing particles to de-
crease particle size, re-forming larger particles with 
specific chemical proportions via granulation, and 
heating and pressurizing re-formed particles into 
a polymer carrier. These final polymer carriers are 
then condensed into thick capsules composed of 
gelatin and cellulose.3 Irrespective of slow produc-
tion rate and high costs, the traditional mechanism 
of drug production is impersonal and ineffective in 
addressing individual differences between patients.4 
Aprecia Pharmaceuticals, the company behind Spri-
tam, utilizes 3D printing to produce its revolutionary 
drug. Relying on its patented ZipDose® Technolo-
gy, the first step in the producing Spritam is the re-
lease of a thin layer of powdered medicine. Liquid is 
then added to the powder, and particles are bound 
together. The process can be incrementally repeat-
ed to adjust dosage to individual patients’ needs.
     3D-printed drugs have the potential to re-define 
the field of pharmaceuticals. For starters, 3D-print-
ed drugs are porous due to the binding liquid and 
multiple layers polymerized during printing. The 
highly porous nature of 3D-printed drugs results 
in rapid dissolution (within seconds) upon con-
tact with water. Rapid dissipation is essential in en-
suring fast and strong dosage delivery. The exterior 
coat of 3D printed drugs yields improved taste, and 
is perhaps the most palpable benefit for parents 
who struggle in convincing their sick children to 
take medicine. Nonetheless, the ability of patients 
to print their own medicine presents itself as the 
most noteworthy potential benefit of 3D-printed 
drugs. Zipdose’s repeated dose addition method al-
lows patients to produce drugs catered to their own 
specific physiology with exact doses. 3D-printed 
drugs offer an intensely-personalized, accessible, 
and cheap alternative to traditional pharmaceuticals.
     As 3D printing technology becomes further re-
fined, commercially-produced drugs such as Spritam 
will soon be produced not in factories but instead in 
patients’ own homes. As long as the patients’ home 
3D printer is stocked with the necessary ingredients, 
synthesis of any desired drug is possible. The future 
of drug production parallels the steps of home cook-
ing: finding the desired recipe, downloading a copy, 
and cooking the food, except with 3D printing drugs, 
the 3D printer does all the “cooking” for you. Signifi-
cant research and development is in progress to make 
home-printed drugs a reality with in-vitro testing of or-
3D Printing and the Future of Pharmaceutical Practice
Ethan Wang 
D I Y  D R U G S
editor: Kevin Ye // designer: Parker Spradley
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ganic polymers and development of oral films already 
underway.5 Moreover, The FDA has been receptive to 
the integration of 3D printing into medical technology 
and has dedicated two of its official science and engi-
neering laboratories to study the medical applications 
of 3D printing. The approval of Spritam itself stands as a 
compelling example of the FDA’s commitment to bring-
ing 3D printing to the forefront of drug production.6
     The groundbreaking development of 3D printing 
drugs; however, comes with a host of access barri-
ers. Despite the FDA’s declared intent to further 3D 
printing technology, FDA commissioner Scott Got-
tlieb has admitted that numerous difficulties exist in 
regulating such a novel field. In December 2017, two 
years after the approval of Spritam, Gottlieb remarked 
that the FDA is still “working to establish a regulato-
ry framework for how… [they] plan to apply existing 
laws and regulations that govern device manufacturing 
to non-traditional manufacturers like medical facil-
ities and academic institutions that create 3D-print-
ed personalized devices for specific patients they are 
treating.” Yet, beyond ambiguity in the application of 
existing laws to 3D printing, Gottlieb does not ad-
dress what might be the most impactful benefit of 
3D printing - integration into patients’ households. 
     Difficulties in the regulation of drugs produced in 
patients’ homes may be responsible for the FDA’s inabil-
ity to fully commit. Currently, the FDA is responsible 
for the regulation of medical devices, electronics, and 
both prescription and non-prescription drugs. Catego-
rization of 3D drugs may seem intuitive. But, what if a 
patient prints a tablet of over the counter aspirin and 
then prints a tablet of physician-prescribed fentanyl? 
Both tablets are drugs, but one is a prescription drug 
and one is an over the counter drug. Extraordinary at-
tention to detail must be exercised in discriminating 
ideal regulatory practices between different drugs. In 
addition, the customizable nature of 3D drug produc-
tion is a problem in and of itself. If patients can print 
drugs with a theoretically infinite number of chemical 
combinations, is it the FDA’s responsibility to regulate 
every single combination? Even beyond 3D-printed 
drugs themselves, the FDA must also address regu-
lation of the 3D printer. Although the FDA regulates 
medical devices and electronic products, regulation 
has never been required for personal devices that pro-
duce a secondary pharmaceutical product. Questions 
like these lack clear answers and contribute to the reg-
ulatory nightmare surrounding 3D drug production.7
     However, historical FDA precedent may provide 
insight into the best method of regulation. Patient-cus-
tomized tracheal implants produced by 3D-printing 
have been approved before and are not exception-
ally dissimilar to the patient-customized nature of 
3D-printed drugs.8 On the issue of drug categori-
zation, 3D printed drugs can divided into over the 
counter and prescription drugs and regulated accord-
ingly in each category, and to address the potentially 
infinite number of drug combinations, the FDA, al-
ready responsible for regulating drug strength, could 
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set upper and lower bounds on acceptable drug com-
binations and concentrations instead of attempting 
to regulate all possible combinations individually.9
     Economic concerns are an additional access bar-
rier. 3D printing is not a cheap process. The cheap-
est high-quality 3D printers available for commercial 
purchase cost at least $300, and high-end 3D print-
ers similar to 3D printers used in Aprecia Pharma-
ceuticals’ factories can cost over $10,000.10 Substan-
tial technological advancement must occur for 3D 
printers to be affordable for the everyday American. 
Patients interested in the customizability and accessi-
bility of 3D printed drugs will have to recognize the 
significant investment involved in buying a 3D printer. 
     Furthermore, big pharma has taken advantage of 
consumers before, and may continue doing so by hik-
ing up prices for 3D printers and chemical ingredients. 
Consider the case of Martin Shkreli, former CEO of 
Turing Pharmaceuticals, as a warning. Shkreli, who 
acquired the rights to Daraprim, an anti-infection 
drug essential in the treatment AIDS, and raised its 
from $13.50 to $750 a pill, an increase of over 5000%. 
Though Shkreli later lowered the price of Daraprim to 
$375, the drug is still inaccessible to lower-income, un-
insured patients. Shkreli is not the exception to the rule: 
Marathon Pharmaceuticals recently raised the price of 
deflazacort, a muscular dystrophy drug, to $89,000.11 
The nature of pharmaceutical economics itself explains 
the rampant exploitation of consumers. Pharmaceuti-
cal companies’ income rises as drug sales and prices 
increase, regardless of how effective the drugs are. 
This profit-centric mindset biases how pharmaceutical 
companies fund medical research and design drugs. 
     Yet, the unavoidable influence of big pharma may pro-
duce certain benefits. Through patent protection, vast 
economic resources, and significant capital for R&D, 
these companies are able to sponsor and produce new 
drugs at a high rate. Even though money may be a sig-
nificant factor in big pharma’s daily operation, a recent 
study at Columbia University found that “from 2000 
to 2009… pharmaceutical innovation added 1.23 years 
to the average lifespan.” The study relied on a causal 
model to eliminate biased estimates and improvements 
due to extraneous factors such as income, education, 
and immunization.12  Whether beneficial or not, the 
presence of big pharma begs another question - if 3D 
printing is patented by big pharma, what happens to 
the everyday pharmacist? University of Wisconsin pro-
fessor and executive director of the American Institute 
of the History of Pharmacy, Gregory Higby, remarks 
that Aprecia’s 3D printing technique sounds “like a 
return to the days of pharmacy compounding except 
that a machine is producing the pills instead of a phar-
macist. In other words, 100 years ago, any pharmacist 
could mix together active and inactive ingredients to 
the specific strength prescribed by a physician for a pa-
tient. Now, you apparently tell the ‘printer’ to do it.”13 In 
spite of Higby’s commentary, 3D printing is far from a 
death sentence for pharmacists’ jobs. Pharmacists per-
form a variety of middle-man functions including but 
not limited to ensuring drug safety, providing guidance 
on side-effects, consulting with doctors responsible 
for drug prescription, providing pharmaceutical ad-
vice to patients with advanced diseases, and checking 
against the improper sale of drugs for non-medicinal 
purposes.14 For now, at least, pharmacists’ jobs are safe.
     Susceptibility to hackers and black market influence 
may be the scariest implication of 3D printed drugs. 
3D printing, reliant on printers wirelessly linked to 
a controller PC, is substantially more vulnerable to 
breaches than traditional manufacturing processes. 
Hackers can alter preloaded recipes on patients’ com-
puters in a manner such that visual differences between 
the edited and original 3D product are imperceptible. 
During this process, hackers may not only access con-
fidential patient data, but also mis-produce drugs and 
harm patients. 3D printed drugs may transform large 
hacking events into national health crises. Hacked and 
counterfeited 3D printers can also be purposed for 
the production of illegal drugs. From basic chemicals, 
drug dealers can synthesize street drugs en masse in 
an easily-packaged, dispensable form. Alternatively, 
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3D printing may replace in person drug deals with 
printer recipes and mailed ingredients.15 Two imple-
mentable provisions may curtail the impacts of hack-
ing and black market trade. First, recipes sent by phy-
sicians to patients could be encrypted such that only 
the healthcare provider and patient can access them. 
Second, recipes could be programmed such that they 
are only printed with doctor and pharmacist autho-
rization. With these two provisions in place, the bat-
tle ultimately still rests on two opposing forces: the 
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skill of hackers and the strength of data encryption.16
     Still, despite these potential issues, 3D printing 
technology has the ability to extensively improve 
the processes of pharmaceutical manufacturing and 
drug development. Personal customizability and 
drug convenience are huge boons of 3D printing, 
though understanding risks is essential in moving 
forward; nonetheless, 3D-printed drugs have the 
potential be a major turning point in drug produc-
tion, forever redefining the pharmaceutical industry. 
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Computerized_Markets
Will Artificial Intelligence Take Over Wall Street?
James Kiraly 
0100101101010
In this day and age, “machine learning”, “ar-tificial intelligence”, and “big data analysis” are important buzzwords that represent the 
forefront of modern technological innovation. 
They have infiltrated almost all aspects of our 
society, from self-driving cars and automated 
warehouses to our cell phones, with processes 
such as Siri or Cortana.  However, the great-
est question is: what comes next? Artificial 
intelligence has the potential to revolutionize 
the corporate landscape, but no one knows 
the consequences of this technological revo-
lution.  What markets or industries will it in-
filtrate, and what will be the consequences of 
this “take-over” on the human job market? 
Automation of jobs could lead to cheap and ul-
timately more efficient sources of labor, which 
would result in widespread layoffs and in-
creased rates of unemployment in the impact-
ed sectors. This apocalyptic corporate vision 
seems almost like science fiction, that artificial 
intelligence would have the capabilities of emu-
lating or even perfecting jobs requiring human 
creativity or higher level thinking. However, 
this future may not be as far off as it seems.
     One market that artificial intelligence and 
big data analysis has already infiltrated is in-
vestment banking. In an effort to optimize 
their stock market research and investment, 
more and more funds and large Wall Street 
firms, such as Goldman Sachs, are turning to 
artificial intelligence as a way of cutting back 
unnecessary employee expenditure as well 
as improve their methods.4 Hedge funds like 
editor: Kevin Ye // designer: Parker Spradley 
BlackRock and larger firms such as Goldman Sachs and 
J.P. Morgan have already begun pouring more and more 
money into computer research.  As of last year, Gold-
man Sachs employed around 9,000 computer engineers, 
around a third of their entire staff, dedicated to improving 
and maintaining their technological infrastructure.4  J.P. 
Morgan has recently hired one of the world’s experts in 
machine learning and natural language processing to help 
lead their efforts.3  BlackRock’s Scientific Active Equity 
group, a team centered on studying and using new ma-
chine learning methods of investment already manages 
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$80 billion dollars of the hedge fund’s $286 billion ac-
tive equities, and given the success of their assets in the 
past few years, more and more funds will be managed 
by this automated team of traders in the near future.5 
BlackRock’s SAE team is an experimental investment 
group which is currently researching the efficacy of 
these novel methods, utilizing big data to quantitative-
ly analyze thousands of stocks globally as well as ma-
chine learning to create more accurate market models 
and analyze more qualitative factors such as SEC fil-
ings or press conferences. In the past five years, 90% of 
assets run by BlackRock’s SAE team beat their bench-
mark, as opposed to only 49% run by BlackRock’s tra-
ditional “Fundamental” team.7  In London, large firms 
such as MAN AHL and Winton Capital Management, 
have also begun investigating the potential for machine 
learning and big data’s role in market analysis and 
smart investment.  “It’s at an early stage,” Ledford, 
a chief data scientist at MAN AHL, said. “We have 
set aside a pot of money for test trading. With deep 
learning, if all goes well, it will go into test trad-
ing, as other machine-learning approaches have.”7 
The market of computerized trading through 
learning machines and macroanalysis of big data 
is the new frontier for investment firms, and al-
though it is still being researched and tested, the 
implications of these new technological methods 
have the potential to revolutionize the markets.
     This is only the beginning. Computerized trad-
ers and big data analysis are already able to man-
age thousands of more companies more efficiently 
than human traders and traditional funds can, and 
these methods are only going to improve.  With in-
creased funding as well as attention from enormous 
firms such as Goldman Sachs, J.P. Morgan, and 
BlackRock, more and more money will be invested 
in studying how artificial intelligence could opti-
mize their transactions.  Investment traders are be-
ing replaced by computer engineers and machines, 
and the days of enormous trading floors of analysts 
and traders may soon become relics of the past.
     As these investment firms and funds contin-
ue to further adopt these strategies, the structure 
and organization of how business is conducted 
and carried out will dramatically change.  In the 
Man Group Plc, a group within MAN AHL, the 
chief executive officer, Luke Ellis foresees a com-
plete revolutionization of the markets. “If com-
puting power and data generation keep growing 
at the current rate, then machine learning could 
be involved in 99 percent of investment manage-
ment in 25 years,” Ellis said.8  Computerized trad-
ers and big data analysis are already able to man-
age thousands of more companies more efficiently 
than human traders, and these methods are only 
going to improve as technology improves. It is 
clear that there is significant potential for artificial 
intelligence and its related technologies to almost 
completely automate the majority of investment 
jobs.  However, despite the exciting potential this 
could have on how our economy and how it will 
+ 5.12%
+ 7.36%
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function for years to come, there are many important 
consequences to this revolutionary paradigm shift.
     The first, and perhaps most important, result of 
this change is the implication it has on the job market. 
Why would firms continue to hire market analyst and 
traders when their job could be replaced by a more ef-
ficient, cheaper AI?  At investment firms and groups 
like at Man Group Plc, there could be a huge impact 
on jobs.  Estimates by Opimas, a research consultant 
which studied financial firms, say that around 90,000 
jobs in fund management, market analysis, and staff 
will be gone by 2025, around a third of all of those jobs 
worldwide, due to the implementation of new technol-
ogy demonstrated by MAN, BlackRock, and more.8 
However, even now, we can see these trends in many 
firms like Goldman Sachs.  Just in 2000, Goldman 
Sachs’ headquarters in New York employed 600 trad-
ers, who were in charge of providing for the bank’s larg-
est clients.  Now, there are only 2 equity traders left, the 
rest replaced by computers and their caretakers.4  At 
BlackRock, two top quantitative researchers left, giving 
way to more funding for the innovative SAE group.5 
Although not extremely significant at the present, 
these trends present interesting implications for what 
is to come, especially as artificial intelligence becomes 
more ubiquitous in investment banking.  Predictions 
estimate that in the next decade or two, nearly all jobs 
in analytics have the potential to be replaced, and soon 
there would be no need to employ human traders.  The 
impact of this replacement is self-evident.  The job mar-
ket for investment banking is about to radically change.
     However, the introduction of artificial intelligence in 
investment banking poses beneficial consequences as 
well. Increased efficiency in market prediction would 
allow for greater profits and smarter investment on a 
faster, larger scale, potentially boosting the economy 
and providing greater security for the economy as a 
whole. Improved market analysis could help predict 
and avoid future economic crashes or depressions. 
However, as this technology has never before entered 
the markets in such an impactful way, nothing is for 
certain about how this technology of artificial intelli-
gence and machine learning will change our econo-
my and our livelihood.  For now, it seems that there 
will be a continuation of hybrid firms of machine 
and human minds that has a great power to influ-
ence the corporate landscape in these next few years.
     Finally, this replacement of human jobs with learning 
machines also brings about interesting ethical consid-
erations as well.  Even though computers are becoming 
more and more efficient in completing jobs than hu-
mans, should we allow them to supercede us, or should 
our jobs ultimately rest in our hands?  There must be a 
limit in which machines should be allowed to replace 
our economy.  Since artificial intelligence is already 
penetrating higher-level thinking jobs such as analyst 
positions, it could soon enter even more areas, such 
as scientific research or management, and although, it 
seems that this is the logical direction for which our so-
ciety should head, the unknown consequences are fairly 
frightening. Economically, what will happen to unem-
ployment rates, and how will people be able to support 
themselves as the job market grows ever smaller? Right 
now, our society is in a strange transition state: a hybrid 
of machine interference and traditional manpower. 
Though a completely automated society could be utopic, 
this transition of “power” from people to machine may 
have many unintended consequences, and as this prev-
alence of machines in the workplace increases, find-
ing this balance is becoming increasingly important.
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 Evolution 
The study of evolution tells us that we are allowed to fear snakes, spiders, and rats. Both snakes and spiders bite us, and rats spread disease. With the advent of the 
modern age, we learned to fear moving cars, which can hit us, and towering heights, 
which can lead us to instantaneous death by a simple fall. But what is it about ghosts, 
about monsters and creatures of the dark, that terrify us so much? Why does something 
that hasn’t even been scientifically proven to exist keep us up at night? The answers to 
these questions may lie in the field of the most perplexing emotion: fear. 
Fear can be described as “an unpleasant often strong emotion caused by an antici-
pation or awareness of danger.”1 The main function of fear is to act as a natural warning 
signal for the body. Fear triggers specific adaptive responses to any dangers, threats, or 
conflicts. This definition of fear implies that a fear of the supernatural entails a direct 
threat to the human body by some sort of external force. There is a strong sense of un-
usuality in how the human body can discern such a direct threat from something that 
has not even been proven to be real. Particularly, supernatural beings are an entity that 
cannot physically stimulate any fearful response as there is no way that they can interact 
with any of the human senses. As a result, this fear of the supernatural is a baffling one.
Given that fear is one of the most mysterious emotions, it is no surprise that there 
have been many theories surrounding the origin of fear and how it is processed by the 
brain. Specifically, the answers to these questions may be found in theories of emotion. 
Early on, psychologists and physiologists were concerned with figuring out whether or 
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al experiences. One particular theory of emotion is that of 
psychologists William James and Carl Lange, who proposed 
that physiological changes occurr before the emotional per-
ception of a particularly fearful stimuli. Specifically, fearful 
stimuli, such as the sight of dangerous creatures in the case 
of fear, reach the cerebral cortex and lead to occurrences of 
visceral changes.2 These visceral changes are then perceived 
as emotion. Many critics of this considered the theory that 
human emotions could have such a large connection to the 
physiological body absurd. Some believed that the answers 
to the question of human emotion lied in a directly neuro-
logical basis. Cannon and Bard, two such critics, proposed 
that the neurological aspects of emotion lie underneath the 
cortex and involve the thalamus. Others took a more psy-
chological approach. For instance, John B. Watson, known 
as the father of behaviorism, devised a theory in which all 
emotion was divided up into three categories and was influ-
enced by three sets of specific stimuli: fear, love, and anger. 
Despite other theories, the James-Lange theory remains the 
closest to the truth in describing the origin of fear due to 
its basis in both physiology and psychology, but cannot ex-
plain fears of concepts which have no direct ability to cause 
a physiological recognition of stimuli. Unsurprisingly, one 
such concept is that of the supernatural, as the concept of 
this can not interact with any of the human senses and thus 
cannot elicit a physical response. As a result, the fear of the 
supernatural may have to be taken as a completely abstract 
fear, paralleling other types of fear such as the fear of lone-
liness and the fear of failure. 
Physiologically, we experience fear when our sensory 
organs detect particular stimuli and transfer information 
about said stimuli to the brain. The typical symptoms felt 
in response to fearful stimuli are those characteristic of a 
“fight or flight” response - a racing heart, fast breathing, 
and other involuntary physiological reactions involved in 
the the brain. This response describes the autonomic ner-
vous system, or the portion of the nervous system that is 
responsible for the control of unconsciously directed bodily 
functions. The involvement of autonomic activation in the 
fear response has led to propositions that stimuli leading 
to fear activate parts of the brain such as the limbic system 
and the locus coeruleus. Particularly, the locus coeruleus 
is involved with stress and panic, directly suggesting that 
the emotion of fear may have a heavy foundation in this 
location of the brain. Although the supernatural cannot 
provide any reliable and consistent fearful stimuli to result 
in such a flight-or-flight response, there must be some psy-
chological reason as to why a fear of the supernatural leads 
to similar symptoms. Despite this, in the case of the super-
natural, there exists no concrete stimuli as the cause of its 
fear. As a result, the direct cause of this fear may not always 
OF   FEAR
the
The Triple Helix | 17 16 | The Triple Helix 
be comprehended consciously. 
Particularly, one of these fears is the fear of the un-
known, as this abstract fear refers to nothing physical 
or tangible. The inability of this fear to be understood 
as connected to any specific stimuli exhibits the conun-
drum at hand.  Specifically, there is nothing set in stone 
in our knowledge to determine why humans fear the 
unknown, or in our case particularly, the supernatural 
world.2 As a result, understanding the human fear of 
the unknown may be the first step in bringing us closer 
to answering the question of how our fears of the su-
pernatural are manifested.
The fear of supernatural beings may be based in 
the fact that humans are genetically predisposed to fear 
anything unknown, anything new to them that may 
pose any sort of threat.3 Certain studies have shown 
a negative correlation between a fear of paranormal 
experiences and a tolerance of ambiguity.4 In other 
words, those who have fears of the supernatural world 
tend to be much less tolerant of ambiguity, or the un-
known, than those who do not possess such fears. This 
suggests that there indeed exists a positive correlation 
between a fear of the unknown and a fear of paranor-
mal activity. 
Specifically, the most probable evolutionary fear 
that is manifested in the fear of the supernatural is the 
fear of death. Humans are predisposed to fear anything 
that has the chance of leading them to death. Reason-
ably, the fear of death is a rationally based fear, and 
thus the fear of the unknown or the supernatural can 
also be described to have this quality.5 The supernatu-
ral world has not been proven to be directly harmful to 
humans in the way that death can be, but both death 
and the supernatural have the quality of always being 
a possible threat. Even though neither are grounded in 
empirical fact, both manifest a similar general fear of 
the unknown. Thus, the two are heavily connected.
In an anthropological view, to many religions, 
death and supernatural beings serve as an entryway to 
a different world, to an unpredictable place.  For exam-
ple, in Islam, there exist jinns, or creations of God that 
live in a world parallel to humans and can lead humans 
astray to this unknown world. In Roman Catholicism, 
ghosts manifest as malevolent spirits and demons that 
reside in hell. In Buddhism, ghosts are reincarnated 
humans that are meant to work out bad karma and live 
in a distinct, other world. These examples are few of 
many that demonstrate the unpredictability of the su-
pernatural. As a result, the fear of death may represent 
the ultimate fear of humanity, that is, of the unknown.
As shown, the themes of death and the fear of the 
supernatural are found in many cultures, as there exists 
a large cross-cultural belief in the supernatural world 
as grounded in religion. Although specific religious 
beliefs, such as of specific gods and myths, may not all 
be the same across cultures, universal themes exists, 
such as that of an afterworld and of supernatural be-
ings.6 This in turn shows how prevalent these fears are 
in the global community, and that they are, in turn, a 
universal fear. It is also possible that humans develop 
a fear of ghosts and monsters to reinforce their own 
religions, as humans need a negative force that contrast 
with the gods they do believe in. In other words, any 
concept, especially abstract ones like religion, cease to 
persist steadily without a conflicting ideal or negation. 
Additionally, belief in opposing forces in religion, such 
as heaven and hell, can enforce a delicate balance in 
beliefs, strengthening community and cultural ties in 
a group.
Understanding concepts of abstract fears such 
as the fear of the supernatural may help us solve the 
current issues of the world more effectively. For ex-
ample, interpreting the human fear of the unknown 
could allow us to improve mental health diagnoses 
and treatments. Better understanding our own emo-
tional psychology could provide headway in treating 
some of the most worrying mental illnesses in society. 
Many anxiety disorders, such as bipolar disease, panic 
disorder, and certain phobias have been found to have 
underlying causes of increased sensitivity to unknown 
threats, or more generally, of the fear of the unknown.7 
Determining common patterns among such anxiety 
disorders would allow for more precise treatment, 
prompting developments of drugs targeted specifically 
for sensitivities to unknown threats.
On a more global scale, our fear of the unknown 
can be taken in context of national security. Particular-
ly, the unpredictability of terrorism and the inherent 
human fear of unknown cultures may have resulted 
in heightened national security around the world, and 
particularly in the United States. The events of Sep-
tember 11, 2001 indicated an unpredictable threat that 
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undeniably resulted in danger, causing elevated levels 
of fear and anxiety among the population. Particularly, 
this event was followed by an increased perception and 
fear of risk, which was further amplified by the media 
and led to unwarranted hatred and subjugation of cer-
tain cultural groups. Consequently, this fear of unpre-
dictable terrorist attacks has been especially significant 
in today’s society given new technologies and a more 
politically divisive global climate. Thus, understanding 
this fear of the unknown in the context of both national 
and international society may be crucial in establishing 
a more stable and tolerant global community.8
Although there exists no concrete or scientifically 
proven answer to why humans fear the supernatural, 
the answer may lie in our fear of the unknown. Years of 
evolution have granted humans the gift of an incredibly 
complex and intricate mind, which as a result leads to 
complicated abstract concepts such as the fear of the 
unknown. Furthermore, the unique human experience 
shapes our fears, as we manifest fears of absurd con-
cepts and objects. Consequently, our fears of ghosts 
may just be reflections of our inner complexity that is 
so inherent in our nature, giving particular concepts, 
such as the supernatural world, particularly mystifying 
powers as something to be feared.
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In a 2011 study, researchers decided to explore col-lege-student discussion of Adderall® on Twitter.1 They combed through 213,633 tweets from 132,099 unique 
user accounts that mentioned Adderall®. Although most 
tweets were sarcastic, joking, or casual, 12.9% of tweets 
mentioned an ‘alternative motive’ in the same tweet; 
specifically, these tweets concurrently mentioned Ad-
derall with studying, finals, tests, and the like, suggest-
ing a potential for misuse. But regardless of the nature 
of these tweets, Adderall®, and by relation prescription 
stimulants, have become normalized, as these tweets 
demonstrate. And although there is nothing inherent-
ly wrong with mentioning these drugs in artforms like 
rap or in jest, reinforcing the idea that these practic-
es are not only commonplace but also acceptable can 
have serious effects on how students perceive their use. 
     Despite how pervasive Adderall is in mainstream 
culture, the health risks associated with prescription 
stimulant use are largely unknown. In fact, 81% of re-
spondents from a 2007 survey at a large, public south-
eastern research university thought that illicit use of 
attention deficit hyperactivity disorder (ADHD) medi-
cation was either ‘not dangerous at all’ or ‘only slightly 
dangerous’.2 Additionally, a 2010 web-based survey of 
over 3400 undergraduates found that 73.1% of respon-
dents were not worried about becoming dependent 
on ADHD medication.3 However, these beliefs lie far 
from reality. From 2004 to 2011, the number of emer-
gency room visits involving nonmedical use of am-
phetamine-dextroamphetamine (Adderall) increased 
from 2,303 to 17,202, a stunning 650% increase.4 The 
normalization of prescription stimulant use has result-
ed in students perceiving the drugs to be merely ‘tools’ 
that can allow them to thrive and succeed in school, 
like a set of flashcards or the internet. But in reality, 
prescription stimulants are incredibly dangerous drugs 
when used by the wrong people for the wrong reasons. 
     Prescription stimulants like Adderall®  are one of 
many classes of central nervous stimulants, ranging in 
the strength of a cup of coffee to that of cocaine. The 
mechanism of action for these types of drugs involves 
an increase in norepinephrine and dopamine levels 
within the prefrontal cortex, the part of the brain as-
sociated with decision making and moderating so-
cial behavior.5 Those with ADHD have lower levels of 
these neurotransmitters, but prescription stimulant 
use largely compensates this deficiency, allowing these 
individuals to function as well as their counterparts. 
For non-ADHD prescription stimulant abusers, pre-
scription stimulant use floods the central nervous sys-
tem with an excess of neurotransmitters because their 
baselines are already normal. These users generally 
report overall increased cognitive function, focus, and 
wakefulness as well as improved mood. It’s exactly for 
these side effects that students abuse prescription stim-
ulants like Adderall® to boost academic performance. 
     But despite the potential positives from abusing 
prescription stimulants, a huge number of both acute 
and chronic health consequences may also manifest, 
which, as mentioned above, are largely not known 
by the public. In addition to enhancing memory and 
alertness, these same neurotransmitters cause an in-
crease in blood pressure, heart rate, and breathing, 
while also decreasing blood flow.6 Users with heart 
issues can experience irregular heartbeat, circulation 
failure, and even heart attack. Additionally, prescrip-
tion stimulant use has been shown to cause mental 
health issues, ranging from restlessness and tremors 
to paranoia, aggressive behavior, and hallucinations.6 
Even worse, these prescription stimulants, like many 
other drugs, can cause both tolerance, dependence, 
and addiction.6 Chronic drug use changes the bio-
chemical balances in the brain, resulting in an elevated 
baseline that increases tolerance to the drug and reduc-
es its efficacy at a consistent dose. Without higher dos-
ages, abusers would be unable to attain the desired ef-
fect from the drug. Additionally, developing tolerance 
to prescription stimulants can also result in a reduced 
dopamine-receptor feedback loop, which can result 
in fatigue and depression.7 Cravings and withdrawal 
“Prescription stimulants can cause 
tolerance, dependence, and addiction.”
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symptoms are also not uncommon among chronic us-
ers, making everyday life difficult to manage without 
the drug and further fueling the dangers of addiction. 
     Nevertheless, students will abuse prescrip
 
tion stimulants because the perceived potential of 
improved academic performance outweighs both the 
ethical issues and associated health risk factors. From 
the same 2007 study, researchers additionally record-
ed undergraduate responses regarding their different 
justifications for illicit study drug use.2 One relevant 
rationalization is the ‘minimization argument’, in 
which students ‘minimized’ the serious nature of pre-
scription by characterising them as ‘harmless, benign, 
and socially acceptable anti-fatigue aid’ by comparing 
these drugs to the likes of coffee, soda, and energy 
drinks. Another major rationalization was a ‘moder-
ation’ argument: they believed they were ‘responsibly’ 
using them only when needed, rather than abusing 
the drug like a hard addict. Whether they are mini-
mizing the consequences of their own risky behaviors 
or that of the drug itself, these students are putting 
themselves into dangerous situations because they do 
not understand the severity of their actions.   
     Additionally, some prescription stimulant abusers 
may understand that potential physical and psycho-
logical risks exist, but will abuse prescription stimu-
lants anyway out of perceived necessity. A 2005 New 
York Times article includes anecdotes from students at 
Columbia University and their struggle to stay afloat 
in a competitive academic setting.8 Some students 
believe that without Adderall® or Ritalin®, they would 
not be able to maintain their high grades. Other stu-
dents, aware of study drug abuse by their peers, bring 
up issues of fairness in the classroom. Some use the “if 
you can’t beat them, join them” mentality as justifica-
tion for their own stimulant abuse, despite awareness 
of the ethical dilemmas behind doing so. Although 
competition and stress can bring out the best in some 
people, others will crumple under the pressure, turn-
ing to these drugs as a save-all and exposing them-
selves to dangerous side effects.  
     The reality of prescription stimulant abuse among 
college students has been driven by a number of 
hidden factors. One huge component of this phe-
nomenon can be attributed to higher prescription 
drug use overall in the past twenty years. In one study 
conducted from 1999 to 2012, researchers observed 
a sizeable increase in prescription drug use among 
US adults, from 51% to 59%.9 Another study came 
to a similar conclusion, finding a 44% to 48% change 
in prescription drug prevalence from 1998 to 2008.10 
Additionally, total expenditure on prescription drugs 
in the United States has increased by nearly nine-fold 
from 1990 to 2017, ($40.3 billion to $360.1 billion).11 
The considerable spending on prescription drugs and 
pervasiveness of their use indicate that these drugs, 
including prescription stimulants, are much greater in 
quantity compared to the past.  Whether this appar-
ent excess is a result of the influence of the pharma-
ceutical industry or changes in medical practice, the 
availability and consequent accessibility of these drugs 
certainly contribute to its normalization, where seem-
ingly anyone can be using them. 
     It is no coincidence that the increase in prescrip-
tion drug availability is correlated to the increase in 
ADHD diagnoses. The National Health Interview 
Survey, a study run by the Center for Disease Con-
trol and Prevention, observed a 66% relative increase 
in ADHD diagnoses since 2000 (absolute rates: 6% 
to 10%).12 One legitimate explanation could be that 
conditions like ADHD can be detected more fre-
quently now due to improved medical practice and 
awareness. However, with the definitive rise of illicit 
Adderall® use and interest, it is completely plausible 
that some cases are fabricated. Not only are symptoms 
largely self-reported, but it is also very obvious which 
responses are associated with ADHD, so patients can 
easily manipulate doctors by feigning symptoms of 
hyperactivity and restlessness. And unfortunately, not 
much can be done on the provider side to stop these 
patient hijinks. In a healthcare system where prescrib-
ers are at the mercy of patients’ satisfaction, fear of 
being sued for mistreatment or negligence may force 
prescribers into complying.  
“Nevertheless, students will abuse prescription stimulants be-
cause the perceived potential of 
improved academic performance 
outweighs both the ethical issues 
and associated health risk factors.
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     With how commonplace and easy it is to access 
prescription stimulants for personal use, it can be 
hard for students to say no. Competition and fear of 
failure can also push people to using these drugs. On 
the other hand, personal moral complications, issues 
of fair use, and legality may leave students conflicted. 
But for whatever stance any individual has on the 
subject, everyone needs to understand the health risks 
and consequences of use. Prescription stimulants are 
drugs, and need to be viewed as such. Although there 
are definitive short-term benefits from prescription 
stimulant use, in time, the consequences from these 
ill-advised decisions can have a huge impact on future 
health and quality of life.
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The fact that the first successfully cloned pri-mates were born less than 100 days ago serves 
as a testament to the continuing interest and ad-
vancement in the field of mammalian cloning. 
The birth of Dolly the sheep at the Roslin Insti-
tute in Edinburgh over 20 years ago sparked the 
intense curiosity and debate surrounding the 
field of cloning that continues even today. Dolly’s 
birth–and more importantly, the way in which she 
was conceived–is considered a scientific break-
through, with some even calling it one of the most 
significant of the century. The commotion sur-
rounding Dolly stems from the pioneering nature 
of the science behind her conception.
Contrary to popular belief, Dolly was not the 
first cloned mammal, but she was the first mam-
mal to be cloned using an adult somatic cell. The 
science behind the technique used, somatic cell 
nuclear transfer, is relatively simple. Scientists take 
DNA from the nuclei of fetal somatic cells—any 
cells in the organism other than the reproductive 
cells—and implant it into “empty” eggs that have 
had their own DNA removed. The scientists then 
stimulate the eggs with an electric shock, and the 
cells begin to divide and develop into embryos. 
These embryos are then implanted into a surro-
gate mother’s womb, where they can develop into 
healthy, viable offspring.1 In the 20 years since 
Dolly’s birth, scientists have cloned over 20 differ-
ent species of mammals using the same technique 
used for Dolly. However, they were unable to suc-
cessfully clone primates, our closest nonhuman 
relatives, until recently.2
Enter Zhong Zhong and Hua Hua, two genet-
ically identical long-tailed macaque monkeys that 
were born in Shanghai in late 2017.3 Like Dolly, 
the monkeys were not the first cloned primates, 
but rather the first cloned primates to be pro-
duced through somatic cell nuclear transfer. The 
fact that primates are so closely related to humans 
makes their successful cloning extremely useful in 
the study of human diseases. Alzheimer’s disease, 
for example, is a chronic neurodegenerative dis-
ease that starts slowly and progressively worsens, 
following a pattern of both cognitive and func-
tional impairment. Its cause remains a mystery 
to researchers.  Currently, about 70% of the risk 
of Alzheimer’s disease is attributed to genetics, 
and the other 30% is attributed to external factors 
such as injury and pre-existing conditions like hy-
pertension and depression. Although researchers 
have tried to identify specific risk genes, this can 
be difficult and problematic due to fact that the 
contributions of each single risk gene is small, and 
it is often a combination of risk genes that need to 
be identified. There is also significant overlap in 
the pathological changes brought about by these 
risk genes and those that can be attributed to con-
ditions like cerebrovascular disease and depres-
sion, often occurring alongside Alzheimer’s.4
The recent developments in primate cloning 
could greatly reduce this kind of confusion when 
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identifying risk genes. The scientists that cloned the 
macaque monkeys propose the possible pairing of the 
new cloning technique with existing gene-editing tools 
(such as the CRISPR/Cas9 complex) in vitro to devel-
op improved animal models of human diseases.2 Using 
this technique, the scientists could produce organisms 
that are born genetically identical with the exception 
of the specific gene being studied, exclusively testing 
potential risk genes without interference from the con-
current effects of other health issues. By keeping the 
clones in a con-
trolled environment and eliminating the external ge-
netic factors associated with Alzheimer’s disease, these 
primate clone models can be used to focus exclusively 
on the genetic causes of the disease.  Scientists could 
use these gene-editing techniques to investigate and 
confirm the roles of individual genes and combina-
tions of genes in causing symptoms. Studying two ge-
netically identical primates can reveal the non-genetic 
risk factors for Alzheimer’s through the observation of 
their effects on genetically identical organisms. If two 
genetically identical monkeys began to develop differ-
ing symptoms when placed in different environments, 
it would make sense to attribute these differences to 
purely environmental factors. The benefits and advan-
tages conferred by cloned primate disease models in 
identifying risk genes is not restricted to Alzheimer’s 
or neurological disorders alone; scientists hope to har-
ness this technology and apply it to a wide variety of 
diseases, including various cancers. 
Another useful application of these primate dis-
ease models is the option to test any drugs or alternate 
methods of treatment that might develop on the cloned 
models before going to clinical drug trials with human 
subjects. Primates are ideal candidates for the testing 
of treatments or drugs because of their likeliness to re-
act in a way that mimics the reactions in the human 
body.5 Furthermore, cloned primates offer a significant 
advantage over their non-cloned counterparts due to 
the fact that in experiments with the latter, it is often 
difficult to determine whether the differences between 
test and control groups are caused by the treatment or 
pre-existing genetic variation. Cloning eliminates ge-
netic background variability, making it easier to tell if 
the differences between test and control groups are be-
ing caused by the treatment being tested. 
However, the use of primates for drug trials also 
draws attention to the ethical implications of cloning. 
Does testing drugs on primates and other mammals 
before moving on to human clinical trials imply that 
their lives are inherently less valuable? What effect does 
cloning have on the value of animal lives? Are clones 
inherently less valuable than naturally born organisms? 
While most scientists and researchers would agree that 
the value of testing drugs on animals comes from a per-
ceived greater degree of dispensability of animal lives 
when compared to human lives, many animal rights 
activists disagree with animal testing and believe that 
it should be discontinued completely. Naturally, it fol-
lows that the advent of clones being used for drug test-
ing will also be met with resistance, perhaps even more 
so because of the fact that many of them will be created 
and brought to this world for the pure purpose of being 
drug testers. 
Even tougher ethical questions can be raised when 
the topic of cloning turns human, and this new ethical 
debate that surrounded possible human cloning start-
ed, once again, with Dolly. The novelty of such a mo-
mentous scientific feat was also coupled with repulsion 
and fear associated with the possibility of a cloning a 
human being. If a mammal as large as a sheep could be 
cloned from a single body cell, would human cloning 
be that far off? 
Those opposed to the concept of human cloning 
were quick to take measures against it: countries across 
Scientists are  hoping 
to harness these tech-
nologies and apply them 
to a widevariety of dis-
eases, including various 
cancers. 
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the world banned human cloning and threatened se-
vere punishment to those who even attempted it. In 
the United States, then-President Clinton called the 
National Bioethics Advisory Committee (NBAC) and 
asked them to “undertake a thorough review of the le-
gal and ethical issues associated with the use of this 
[cloning] technology.” Clinton also asked the NBAC 
to, based on this review, issue a report containing a 
recommendation of what actions should be taken re-
garding human cloning. After the report was released, 
Clinton imposed a ban on federal funding for exper-
iments that involved human cloning.6 The actions 
taken by the government reflected the thoughts that 
many people had regarding human cloning—that it 
was unethical and needed to be stopped. 
However, the scientists that cloned Dolly and the 
macaque monkeys, as well as most of the other scien-
tists who have attempted to utilize cloning techniques 
in their research, have maintained that their main goal 
in cloning mammals was not to potentially clone a hu-
man, but rather as a way to study diseases and their 
mechanisms without endangering human lives.2 Al-
though the researchers have admitted that “technically, 
there is no barrier to human cloning,” they continue to 
maintain that their only purpose is to “create geneti-
cally identical monkeys” for medical research purpos-
es.4 However, the fact that a species so closely related 
to humans was able to be cloned also intensifies the 
ethical debate and reopens the arguments that sur-
round human cloning, specifically. 
The arguments against human cloning are wide 
and varied, but most seem to make their way back to a 
central argument against cloning as being a violation of 
the natural order, tarnishing human dignity.7 Indeed, 
the process of cloning would entirely deprive any clone 
of their own unique identity, which is something that 
most people highly value as a part of being human. It 
would be wrong to impose the genetic identity of one 
individual on another.7 Clones would be faced with the 
unfair pressures of living up to the “standard” set by 
the individual they were cloned from, and might not 
live up to any talents or accomplishments that cannot 
be attributed to pure genetics. Many of the arguments 
against human cloning also carry religious value; a 
common argument that people use against the imple-
mentation of cloning is that it allows scientists to “play 
God,” selecting for and duplicating those traits that 
they find most desirable. Others argue that cloning, 
if used widely in the future, would result in a lack of 
diversity in the population, as people tried to select ex-
clusively for clones with highly desirable traits, phys-
ical and otherwise. Our long history of evolution has 
clearly demonstrated that sexual reproduction and the 
natural selection that occurs as a result of this process 
are extremely advantageous for complex species, such 
as humans, and that it would be dangerous to try to 
interfere with nature.8 
 As of now, laws in the United States continue to 
reflect the ongoing ethical debate that surrounds po-
tential human cloning; the ban on federal funding 
for research using embryonic stem cells from human 
clones still stands.9 Just because human cloning is now 
technically possible doesn’t mean that everyone be-
lieves it should happen, nor does it mean that scientists 
will ever have the legal backing or means of making it 
happen. But, as the recent successful primate cloning 
indicates, there are now technically no barriers to the 
further usage and development of mammalian clon-
ing. Where we believe these new technologies will 
lead is rooted in ethical and moral preconceptions. 
X
X
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T he role of a physician is to ease the suffering of their patients, but what if the best way to relieve their pain involves helping them end their life by committing suicide? The media continues to cover stories of triumph over life-threatening illnesses, spreading the joy ex-
perienced by the victor and their families. Social norms have allowed these in-depth discus-
sions regarding terminal illnesses, but the final moments of patients that don’t overcome these 
diseases are rarely seen in the public eye. For those patients who aren’t lucky enough to broad-
cast their tales of victory, the end of their stories is often unimaginably heartbreaking. But 
what if these less fortunate patients didn’t have to spend their final moments in agony? What if 
their friends and family could say their final goodbyes without watching their loved one suffer?
     These questions echo throughout the debates on 
physician-assisted suicide (PAS) and euthanasia in the 
United States. Physician-assisted suicide and euthana-
sia are alternative end-of-life treatments for mentally 
competent, terminally ill patients that are not legal in 
the majority of U.S. states. Voluntary active euthana-
sia is the process by which physicians administer a le-
thal agent, or a lethal dose of a therapeutic agent, to 
their patient, resulting in death.1 In this case, the phy-
sician directly ends the life of their patient, following 
the patient’s request. Physician-assisted suicide, on 
the other hand, occurs when a physician helps their 
patients to commit their own suicide, typically by pre-
scribing drugs that will end the patient’s life.1 The most 
common prescriptions are for oral doses of barbitu-
rates, a class of sedative medication, to be mixed with 
juice or another liquid for ingestion.2 However, these 
practices are not legal in the majority of U.S. states 
due to the associated ethical and legal uncertainties. 
     Physician-assisted suicide, unlike the more con-
troversial euthanasia treatment, has been legalized 
in six states and Washington D.C. The legalization of 
physician-assisted suicide has been widely debated 
in the medical community for decades, with varying 
opinions emanating from healthcare professionals, pa-
tients, and patients’ families. The American College of 
Physicians recently noted several groups that strongly 
advocate for assisted suicide to promote patient auton-
omy but believed the most compelling arguments on 
the issue came from the opposition, concluding that it 
does not support the legalization of physician-assisted 
suicide.3 Similarly, the American Medical Association 
(AMA) officially opposes PAS. However, as of 2018, 
the Washington D.C. chapter and the AMA chapters 
in ten states have converted to a neutral position.2 
Physician-assisted suicide is now supported by several 
associations, including the American Medical Student 
Association and many others.2 The complex relation-
ship between physicians and their patients creates a 
moral grey area in this debate, with both sides citing 
the legal and ethical implications of these treatments.
     Health care professionals are often drawn to their 
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field because they feel incredible compassion for peo-
ple in need of help. This may translate into the de-
sire some physicians feel to help their terminally ill 
patients die with as much dignity and as little pain 
as possible. In fact, a 2010 study revealed that 40% 
of physicians, nurses, relatives, and lay people sup-
ported the legalization of speeding up a terminally ill 
cancer patient’s death.4 In 2016, Medscape conduct-
ed a survey in which 57% of medical doctors were in 
favor of legalizing PAS, a marked increase from the 
46% found in Medscape’s earlier 2014 poll.2 How-
ever, despite attempts by healthcare professionals to 
minimize their patients’ pain, many patients suffer-
ing from terminal illnesses endure a difficult end. 
     The legalization of physician-assisted suicide is of-
ten supported in debates by discussing the promotion 
of patient autonomy and physicians’ duty to diminish 
the suffering of their patients.2 Allowing patients to 
decide when, where, and how they will die gives them 
the power to take control of their lives before their ill-
ness makes these choices. A survey conducted in 2000 
found that 60.2% of terminally ill patients studied sup-
ported PAS and euthanasia in a hypothetical situation.5 
In the U.S., patients’ autonomy may be infringed upon 
in many states in which physicians are not permitted 
to help their patients end their own lives, giving pa-
tients no choice but to forego further treatment or 
enter into hospice care. PAS is considered by its pro-
ponents to be a compassionate way for a physician to 
help their patient, allowing their patient to die on their 
own terms. Supporters also often provide criteria for 
the legalization of assisted suicide that they believe 
would prevent abuse of this end-of-life care, similar to 
the safeguards in place in states that have already le-
galized PAS. Such criteria are meant to defend against 
the “slippery slope” that many opponents are worried 
will result from the legalization of assisted suicide.
     The “Death with Dignity” laws, which have been 
legalized in five states and Washington D.C., are meant 
to help terminally ill patients end their own lives with 
the assistance of a physician that prescribes them with 
a lethal medication that they are to administer them-
selves.6 The state of Hawaii became the seventh U.S. 
jurisdiction to legalize a PAS law on April 5, 2018, 
which will go into effect on January 1, 2019.7 These 
laws have many careful safeguards in place to prevent 
any possible coercion abuse of such legislation. For ex-
ample, qualifying patients must be mentally competent 
and have a prognosis of six months or fewer to live, 
which must be confirmed by two physicians.6 After 
the required criteria are met, patients may request to 
receive a lethal prescription from their physician. The 
patient may rescind their request at any point in the 
process, thus protecting the patient autonomy that 
both supporters and opponents of PAS consider vi-
tal.6 The final decision to end life, using a lethal pre-
scription, can only be made by the patient themselves. 
     Proponents of PAS often discuss the story of Brit-
tany Maynard, a 29-year-old woman, who was di-
agnosed with terminal brain cancer and completely 
changed her life in order to pursue a dignified death 
in Oregon. After overcoming many obstacles, Brittany 
managed to establish residency in order to fully qualify 
for death with dignity.8 In an article published by CNN 
she said, “I am not suicidal… I am dying. And I want to 
die on my own terms.”8 Brittany obtained the medica-
tion necessary to end her life but did not take the pre-
scription until several weeks later, after her husband’s 
birthday.8 Brittany noted tremendous relief when she 
obtained her prescriptions, and she proceeded to end 
her life on November 1, 2014, with loved ones by her 
side.8 Brittany’s hope was that all Americans would 
have the ability to choose how their life ends and that 
no one take that choice away from people in simi-
lar situations.8 Those who support the legalization 
of PAS often look to stories like Brittany’s to remind 
people that this decision cannot be made solely on 
facts and figures, but real people must be considered.
     While stories like that of Brittany Maynard indicate 
the benefits of legalizing PAS, the opposition consid-
ers the possibility of a “slippery slope” to be too great 
a risk. Opponents often discuss Dr. Jack Kevorkian’s 
actions when describing the possible repercussions 
of PAS legalization. Kevorkian admitted to helping 
130 patients end their lives between 1990-1998 while 
his actions gained publicity for both him and PAS. In 
1998, after many encounters with law enforcement, 
Kevorkian was charged with second degree murder 
after injecting a lethal medication into a patient suf-
fering from ALS. Although this patient allegedly re-
quested Kevorkian’s help, this crossed the line from 
physician-assisted suicide into voluntary euthanasia, 
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which many people believe is equivalent to homicide. 
Citizens cautious of the slippery slope also note that, 
of Kevorkian’s 130 patients, approximately 60% were 
discovered to have no terminal illnesses.9 In some 
cases, autopsies indicated that there was no physi-
cal evidence of any disease in the patient.9 Thus, op-
ponents often use Dr. Kevorkian as evidence of the 
possibility of abuse by physicians and other parties. 
     The possibility of endangering vulnerable groups, 
including those of lower socioeconomic status, is con-
sidered to be a primary reason for opposing this type 
of legislation. The Washington Times reported a sto-
ry about a woman who was allegedly denied coverage 
of treatment for her terminal disease when her state 
passed PAS laws.10 Such a story requires consideration 
of how the economics of health care could be affected, 
especially when PAS is a more cost-effective option. 
Surprisingly, though, the interest in PAS was not found 
to differ significantly among groups of varying age, ed-
ucation, income, length of illness, or physical activity.5 
The safeguards in current legislation are considered to 
be insufficient by opponents of PAS, leaving too many 
opportunities for abuse. Some question whether or 
not the witness present in PAS proceedings could be 
a family member with some kind of financial or emo-
tional incentive to help the patient die.11 Despite no ev-
idence to suggest abuse of current PAS practices, oppo-
nents continue to cite numerous possible examples in 
which abuse could corrupt a system that allows PAS.12
     Oregon, the first state to enact a Death With Dig-
nity Act, provides over twenty years of data and ex-
periences to help shape this debate. While many may 
predict pain to be a primary reason for desiring PAS 
in Oregon, this has not been the case. Loss of autono-
my, including  the loss of physical and mental faculties, 
and decreasing ability to partake in the activities that 
made life worth living were the most common reasons 
patients provided for pursuing a dignified death, with 
91% and 89% identifying these as their primary mo-
tive, respectively.13  These patients are often most wor-
ried about how losing motor and cognitive functions 
will affect their quality of life as their illness progress-
es. Only 26% of patients reported pain as their prima-
ry incentive in seeking out death with dignity, while 
only 4% of patients indicated financial concerns.13 
     Clinical depression has also been found to be a 
major determinant in the likelihood of a patient to 
pursue PAS, and it is a major reason why many oppo-
nents are fighting for more psychological safeguards 
to protect patients suffering from mental illnesses as 
well as physical ones.13 Many dissenters of PAS legal-
ization call for more support for patients with terminal 
illnesses, including more psychological support and 
better hospice and palliative care options. Opponents 
of the legalization of PAS often agree that autonomy 
is an important aspect of end-of-life-care, but they 
continue to believe that physicians should not help pa-
tients commit suicide, especially when depression is a 
facotr.2 Opponents often suggest that, instead of offer-
ing PAS as an easy way out, our society should improve 
current end-of-life care practices and mental health 
support for patients suffering from terminal illnesses.
     The data from Oregon has also disproved the idea 
that patients may be more inclined to pursue PAS if 
they are uneducated or are concerned with finances. 
With most patients having at least some college edu-
cation, the results refuted the idea that patients from 
lower income or uneducated groups would be more 
likely to pursue PAS to reduce burden on their fam-
ilies.13 Furthermore, most patients that requested 
death with dignity were already in the care of a hos-
pice facility, which reveals that other end-of-life care 
options continue to be considered and accessed by 
patients suffering from terminal illnesses.13 This evi-
dence suggests that end-of-life care options are avail-
able for patients that do not wish to end their lives, 
likely providing sufficient care for patients in their fi-
nal days, which opposes the idea that legalizing PAS 
would result in a declining hospice care system that 
drives patients to consider PAS as a more viable option.
     Some states have taken action to legalize physi-
cian-assisted suicide with many stipulations to prevent 
abuse, but there are many more that continue to debate 
this controversial decision. But the question remains, 
where should healthcare providers draw the line when 
it comes to assisted suicide and euthanasia? Consider-
ing the legal and moral implications of legalizing PAS 
may seem simple, but what if it were your mother or 
father that was suffering from terminal cancer? It may 
be easy to take a stand on the issue from an outsider’s 
perspective, but one must consider how opinions may 
change when the issue involves their own family or 
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even themselves. The question of legalization remains 
controversial because it is not a decision that can be 
made solely with our heads, it must also be made with 
our hearts. Physician-assisted suicide will likely remain 
a controversial issue for as long as we live but, with 
greater knowledge and consideration, perhaps our so-
ciety can reach a consensus that satisfies all desires for 
providing the best ending for terminally ill patients.
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In the United States, the opioid epidemic claims more than 115 lives every day. 2015 saw 52,404 lethal drug overdoses, 13,000 of which were related to heroin. That same year, 591,000 Americans had a substance use disorder involving heroin. The risks associated with this drug 
include addiction, heart and lung disease, cancer, mental illness, and infection with blood-borne 
diseases such as HIV/AIDS and hepatitis. Heroin interferes with normal neurotransmitter func-
tion, changing users’ ability to control their level of stress, make rational decisions, learn new con-
cepts, and recall old memories. While the drug is damaging enough on its own, it also functions 
as gateway - roughly 23% of heroin users develop an opioid addiction.1
     With an escalating crisis and no clear heading from 
the federal government, state and local governments 
are starting to consider supervised injection sites 
(SIS). In these sites, users bring their own drugs and 
inject under the watch of a nurse. Proponents of SIS 
argue that they mitigate the risks of drug use by pro-
viding clean needles and emergency care in the event 
of an overdose. SIS also provide important proactive 
services, including first and foremost a way to get in 
contact with drug users, a notoriously difficult group 
to track, and the distribution of information about re-
habilitation services to those who most need them. 
Critics argue such a facility will encourage drug use 
and bring drug users to the neighborhood in which it 
resides, increasing crime and needle pricks in the area. 
     This article will assess to what extent SIS improve 
the lives of their patients, if they will be useful in 
broader societal terms, and how they tie into the na-
tional political debate on the opioid epidemic. Two 
scientific pilot programs, one in Vancouver and one 
in Sydney, will provide the data for this article’s sci-
entific discussion. And to explore the political side of 
SIS, we’ll examine the hurdles surrounding SIS im-
plementation in Philadelphia, a city that opened a 
legal path to creating such a facility but passed the 
responsibility for doing so on to the nonprofit sector.
 
 
Do SIS help their patients? 
     To answer this question, we will examine whether SIS 
prevent overdoses, promote addiction treatment and 
medication adherence, and/or, ultimately, save lives. 
While both the Sydney and Vancouver clinics managed 
thousands of overdose events without a single fatality, 
neither clinic made a perceptible impact on communi-
ty levels of overdose nor overdose presentations at hos-
pital emergency wards. Moreover, the sites saw elevat-
ed rates of overdosing in clinic as compared to on the 
streets, suggesting either users of SIS are a high-risk pop-
ulation, or users take greater risk by using more heroin 
when they are being supervised by health professionals.
     With regards to referral of users to drug addic-
tion treatment, 11% of clients over 6 years were re-
ferred to treatment. This rate has been exhibited as 
evidence that SIS function as gateways for treatment 
and criticized as unjustifiably and abnormally low.4 
With regards to treatment adherence, a 2014 study of 
13 residents of a 24-bed HIV/AIDS care facility con-
cluded SIS are central to a “comprehensive harm re-
duction strategy,” a strategy that improves adherence 
to highly active antiretroviral therapy as well as sur-
vival rates. Additionally, this policy promoted hon-
est discussion of drug use, an important first step to 
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receiving treatment. While small in sample size, the 
study suggests SIS do meaningfully contribute to an 
atmosphere that encourages drug users to seek help.
     Calculating lives saved is a tricky business. While 
there is a debate over the exact rate, there is a consen-
sus that SIS do save lives, but that the rate of doing so 
is low. While the statistics vary by region and clinic, 
hypothetically if a clinic hosted 300 injections a day 
(twice the use of the Sydney site), the clinic would pre-
vent 1 lethal overdose of a patron annually.3 So we can 
conclude that while SIS do not seem to prevent over-
doses, they do promote use of addiction treatment 
programs and adherence to medication regiments, 
and they do save lives. To help answer the question 
of whether the sites do so at an acceptable cost, we 
will next examine the societal impacts of the clinics.
 
Do SIS help the community?  
     To start answering this question, let’s first ask: Do 
SIS decrease public nuisance and the transmission of 
blood-borne viruses? A decade of data from Vancouver 
and Sydney have provided us with some preliminary 
answers to this question. With regards to public inject-
ing, Sydney saw a marginal (at best) decrease in public-
ly disposed needles and syringes because of their SIS. 
Furthermore, Sydney saw no impact on blood-borne 
virus transmission, meaning no demonstrated im-
provement in Hepatitis B infections, Hepatitis C rates, 
sharing/reuse of syringe and injection equipment, nor 
in HIV testing. By these two measures, SIS do not 
appear to help their communities. We have already 
shown, however, that they do appear to help their cli-
ents. So, it is worth asking if SIS do any societal harm.
     SIS have not been shown to increase crime, neither 
petty crime nor drug dealing, in the area surrounding 
the SIS. Furthermore, the clinics have not been demon-
strated to draw drug users or dealers to their area. So 
now we are left with a conundrum. The clinics do 
seem to some good for their patients, and while they 
fail to really impact community health, they do appear 
to help their clients in terms of safety and accessing 
addiction treatment. We thus must look at wheth-
er these clinics are efficient tools for societal good. 
     One way to gauge efficiency is by calculating the 
medical costs that were prevented (such as ER visits, 
drug regiments, etc.) due to the implementation of the 
clinics. Using the conservative estimate that decreased 
needle sharing was the only effect of the Vancouver 
supervised injection facility, the facility was shown to 
be associated with, over ten years, a net savings of $14 
million. For every dollar spent on the site, a different 
calculation found 1.5-4.02 dollars in benefit resulted. 
Despite these encouraging results, experts agree that 
more longitudinal studies (studies that track the same 
variable over years, perhaps decades) are needed. De-
spite these encouraging results, Australia’s health min-
ister stated the money would have been better spent 
on addiction treatment. As you can see, there’s evi-
dence that supports both sides of the scientific argu-
ments for and against SIS. Philadelphia lies in the heart 
of the epidemic. A quick look at the discourse sur-
rounding SIS in this city will help reveal which argu-
ments carry weight with the public and policy makers.
 
Politics Surrounding SIS in Philadel-
phia 
     In January of 2018, Philadelphia city officials okayed 
the creation of a supervised injection site. The city, 
however, will not fund the SIS nor assign it a location 
– two monumental tasks. The city will not even oper-
ate the site, opting instead to help connect users to ad-
diction services. The idea of having a private developer 
run the site has some community members concerned, 
including Councilwoman Maria D. Quiñones-Sánchez 
who represents a district at the center of the crisis. 
Perhaps even more concerning is the fact that such a 
site and its workers would not be immune from fed-
eral prosecution, an especially concerning possibility 
given that President Trump has indicated a desire to 
focus on law enforcement, as opposed to treatment, to 
combat the opioid epidemic. Further complicating the 
clinic’s legal standing, Philadelphia’s police commis-
sioner stated he does not know how the site will affect 
the policing of narcotics; however, he has declared that 
those working at such a site will not be criminalized 
(locally) for trying to stop the spread of disease.10
     The government has always controlled the defini-
tion and criminalization of drug use, and given the 
current laws it enforces, the government will have to 
be a part of any major initiative to treat drug addiction. 
The Triple Helix | 33 32 | The Triple Helix 
While Philadelphia seems to have accepted this, de-
bate remains over whether SIS are the path to take. It’s 
worth noting that the economic incentive for SIS (that 
SIS will save money by reducing the government’s net 
healthcare spending) do not apply in the city, as health-
care savings will primarily go to the federal govern-
ment (as the federal government funds Medicare and 
Medicaid) rather than the Philadelphia municipality, 
the entity footing the bill for the SIS. These economic 
arguments, similar to those revolving around alleviat-
ing stress on penal and mental health care systems, rely 
on long time scales. Simply put, the returns for public 
health investments do not come quickly, making these 
investments difficult for policy makers to sign off on. 
Amidst scientific, economic, and political debate, the 
argument that has gained the most traction has been 
the simple fact that the crisis kills three to four peo-
ple every day and that the city desperate needs to start 
acting now, as there is no quick solution.10 While SIS 
are clearly far from being the silver bullet, they are one 
of the more implementable proposals and th current 
models can, of course, be improved upon with time.
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The course of human history is punctuated by transformative moments of innovation in ideas and tech-nology. The story of medicine is one and the same: from the original text of the Hippocratic oath written in Greece to the development of the germ theory of disease during the Newtonian Age, medicine is a 
organic machine that changes over geography and time. Societies that define notions of health and design the 
system by which it treats those considered ill also morph over time. During the Middle Ages, leper colonies 
were built to quarantine those with leprosy whose physical disfigurations were stigmatized as monstrous and 
contagious. In the 19th century, mental asylums housed patients deemed criminal or insane, as both qualities 
were considered synonymous. In modern times, pathologizing disorders has become increasingly practiced 
through medicalization. 
     Pathologization refers to the act of determining 
what is and is not a medical disease - it is fundamen-
tally an exercise in assigning meaning. The 21st centu-
ry experienced an explosion in rates of new medically 
legitimized social pathologies: social anxiety disorder, 
major depressive disorder, panic disorder, anorexia, 
attention deficit hyperactivity disorder, chronic fa-
tigue syndrome, and so on. This modern process of 
inventing disorders to describe illness is medicaliza-
tion. Medicalization refers to the way in which hu-
man conditions become defined by and treated as 
medical symptoms that then require expert interven-
tion. Emotions, bodily characteristics and behaviors 
once considered non-medical components of human 
existence increasingly become perceived as undesir-
able characteristics to be managed through medi-
cal treatment, diagnosis, prognosis, and prevention. 
This paradigm shift occurs within the growth of neo-
liberalism that emerged in the 70’s. Neoliberalism 
can be defined as a laissez-faire economic system 
that stresses an unregulated market structure, finan-
cial austerity, fiduciary duty, and the privatization of 
services. The dominant rise in the corporate power 
of the pharmaceutical industry could be understood 
through this economic context. Industry, here re-
ferred to as the matrix of corporate-patient relation-
ships characterized by continuous drug development, 
deceptive advertising campaigns and heavy physician 
marketing, operates through this logic of medicaliza-
tion, where the incorporation of once human condi-
tions into new disease markets drives market growth, 
consumption, and innovation. Medicalization trans-
forms the definition of these emotions by framing the 
illness as an internal issue of the psyche, rather than 
a symptom of social structures, that must then be re-
solved through individualized consumption. For exam-
ple, the effect of social alienation is medically licensed 
as a pathology that becomes coined as “social anxiety 
disorder,” the implication being an absence of contin-
ual communication equals the presence of cognitive 
deficiency. The mental states that inevitably develop 
as a result of living in a society plagued with employ-
ment instability, unaffordable housing, environmental 
hazards and materialistic rituals are considered aberra-
tions to be diagnosed and treated. As a result, pharma-
ceutical companies have an incentive to invest profits 
into campaigns to convince the population that how 
they feel is due to medically recognized disorders as 
opposed to recurring effects of societal failures. This 
framing results in the belief that disorders are curable 
only through institutional measures while evading the 
question of how and why they arose in the first place. 
 Take depression as an example. The biochem-
ical state of being depressed is not a uniquely modern 
condition; there have always been individuals who 
have met the criteria for what would now be consid-
ered major depressive disorder. The modern invention 
here resides in how institutions like the American Psy-
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chiatric Association frame that condition as a medical 
pathology, i.e. major depressive disorder. By normaliz-
ing the diagnosis of feelings and behaviors as medical 
disorders, the country has witnessed a 370% increase in 
the diagnosis rate of mental illnesses between 1955 and 
2000. As the umbrella of what is considered depression 
widens, more people are incorporated into its label. 
The treatment response to depression occurs largely 
through the frame of medicalization and strength-
ens the idea that response strategies should revolve 
around medication and individual therapy, as opposed 
to reconsidering social policies and arrangements.
UNIVERSAL PROPHYLAXIS
Modern medicine emerged after World War I when 
political leaders placed their faith in science and ra-
tionalism as the saviors of human problems. Ratio-
nalism is defined as the belief that solutions to social 
problems should be sought on the basis of calculable 
measurements. Since science and industrial produc-
tion won the war, technological progress was believed 
to be capable of resolving all social ills. Mired in the 
belief that all aspects of life could be enhanced through 
rational thought, the human being came to represent 
an autonomous actor capable of solving issues through 
individual grit, hard work, and acting in self interest. 
This logic scales up to the contemporary for-profit 
health care model, where patients act as rational con-
sumers of plans and physicians, and are responsible 
for conducting their own research between a myriad 
of choices. This model is extremely profitable because 
it stresses consumption as the most accessible ave-
nue for care: in 2015, the twenty largest pharma cor-
porations (after deducting research and development 
costs) combined to take in a profit of $31,727,491,000. 
In the 1800’s, medicine was similar to religion; doc-
tors were priestly figures who competed for different 
claims to truth on how to resolve illnesses. Because 
there was no standardized curriculum for medical 
school, doctors prescribed different methods of treat-
ment based on individual experience or superstitions. 
The Flexner Report released in 1910 created the pro-
fessionalization of medicine by defining scientific 
knowledge as the principal ethos of the modern phy-
sician and introduced the challenge of creating a sin-
gle rubric for resolving illnesses while simultaneously 
maintaining the personhood of individual patients. 
However, the presumption of medicine as a pure sci-
ence conceptually reduces human beings into medical 
models to be operated on by expertise driven physi-
cians. Individuals become conceived of as “machines” 
that must be “monitored” and inevitably “break down” 
and cease to function. Once people are abstractly re-
duced to biological machines that either function or 
do not, they can be fixed, measured, or discarded. The 
modern metaphors of illness and disease that perceive 
personhood through functionality emphasize bodily 
malfunctions and biological deficiencies as indicators 
of health or lack thereof. The state of suffering becomes 
explained through a “restitution narrative,” the idea 
that the role of medicine is to return the body to a state 
of “healthy normality.” By stigmatizing emotions asso-
ciated with abnormality (pain, anger, sadness, loneli-
ness, etc.) as deviant pathologies, the restitution narra-
tive allows experts to maintain jurisdiction by forcing 
the sick to defer to impersonal forms of authority (i.e. 
physicians, health commissioners, and specialists) 
in hopes of regaining normality. However, illness-
es and health are much more than top-down models 
of the body; they’re influenced by varying dimen-
sions of class, race, gender, ability, status, and culture. 
 Since the structural determinants of health are 
multiple and the perspectives of what health is differs 
across geography, people have struggled to compile a 
unitary definition of the subject. For example, Native 
American ideas of health directly conflict with neo-
liberal concepts of private property and ownership. 
For native tribes like the Innu, health is intrinsically 
tied to land, ecology, and nomadic life. Through the 
reservation policy, native mobility was confined, spir-
itual connections to the land severed, and native heal-
ing practices discredited by medical practitioners as 
primitive and self-destructive. Modern medicine and 
notions of health were used not to strengthen native 
ties to health, but to replace them. Another example 
is the way disability activists have challenged the tra-
ditional notion of health as synonymous with physi-
cal ability and strength. By contesting the notion that 
disability is an unhealthy illness or a tragedy, activists 
procured an alternative “social model” of disability 
that focused on improving disabling environments as 
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opposed to individual impairments. These example, 
amongst others, demonstrate that a top-down, one 
size fits all definition of health and care is inadequate 
to describe the diversity of social relations and iden-
tities in the United States, and that alternative con-
ceptions of health should be understood to formulate 
policies better attuned to the histories of communities. 
REIMAGINING CONTOURS OF HEALTH
It is difficult to programatically establish nation-
al health insurance without a prior understanding of 
what “health” is, because after all, health is ostensibly 
the object being insured. The nucleus of the modern 
medical system is the belief that health is a marketable 
“commodity” – that is, health is a quantifiable and sci-
entifically measurable state of being that can be formu-
laically achieved with the right medical prescriptions, 
diagnostic tests and technological advancements. As a 
commodity, the distribution of health should be left up 
to markets with the underlying philosophy being that 
those who cannot afford services should remain with-
out them. Yet, health is not a commodity. It is not a 
car where consumers rationally decide between com-
peting options in full knowledge of associated pros 
and cons – much of this knowledge stays insulated 
within the medical profession. There is also no single 
definition of health. Health is not a uniform reality 
that transcends geography and time. It is socially con-
structed and medically conditioned; its definition has 
changed over time and will continue to morph in the 
future. The modern ideal of a healthy body is a con-
ceptual product of a neoliberal society. It is precisely 
this idea of health as profitable commodity that gener-
ates a defunct, inequitable health care system marked 
by skyrocketing premiums, malpractice lawsuits, de-
personalization of the doctor-patient relationship, 
medical fraud, and profiteering conflict of interests. 
The market approach transforms patients into avid 
consumers, generating two noticeable paradoxes. 
Firstly, the consumer oriented model drives health care 
costs way up. Individuals actively seek out excessive 
goods and specialized services for often medically un-
necessary reasons. Consumption in turn drives endless 
production, overprescription, and drug innovation un-
tied to necessary medical progress. Secondly, medical 
consumption operates by engineering the desires of the 
population. Inundated with societal demands to attain 
achieve certain standards of beauty, health, and body 
(the alternative being cased as an unhealthy, diseased 
body), an expansive market structure is established to 
deliver health to insecure consumers. What remains ab-
sent from the political economy of health, care, and in-
surance as an individualized solution to society’s disor-
ders is an analysis of the systematic, cultural forces that 
symptomatically produce illnesses. Societal incubators 
of illness that reflect particular power relations such 
as poverty, inaccessible gender norms, and unprece-
dented levels of wealth inequality remain unaddressed 
in order to export the responsibility of fixing health 
concerns onto the individual consumer, which leaves 
society in a web of rising rates of medical disorders. 
In conjunction with analyzing systematic, neoliberal 
arrangements of society that actively produce health 
concerns, a revaluation of health as an idea must take 
place if society is to envision a democratic spirit of care. 
Is health merely a commodity available to those who 
can afford it or a human right that all are born entitled 
to? Are the ways institutions define and treat illnesses 
neutral or a reflection of particular arrangements of in-
cumbent power interests? Are human beings dignified 
individuals with the right to a reasonable expectation 
to a healthy life or productive machines that function 
and wither away? Reconfiguring the values and con-
ditions of health is critical to formulating politics, be-
cause government policies are not abstractly created in 
a vacuum but rather represent the final trajectory of 
contingent articulations of value. Only once those who 
inhabit societies collectively engage in dialogues over a 
common set of values and what it means to be a healthy 
body can health concerns become a social priority. 
*Check our site for citations.
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Apicture is worth a thousand words, but the phrase “genetic engineering” is worth a thousand pic-tures. The images conjured by genetic engineering (GE) are optimistic, pessimistic, intriguing, 
terrifying, and controversial. But few know what GE can currently do in humans, whether and where 
such things are legal, which applications may be forever out of reach, or just how ineffective our current 
regulations can be. 
Most GE talk surrounds enhancing food, but some research deals in modifying humans. Currently, 
our only GE application in humans is through gene therapy: injecting patients with modified DNA to 
help cure their genetic disorders. These therapies target only specific parts of the body and cannot be 
passed onto the patient’s children, because they don’t modify sperm or eggs19, 27. Some gene therapy 
successes have been achieved in patients with immunodeficiency disorders, Parkinson’s disease, hered-
itary blindness, hemophilia, and more; but the premier examples emerge from the fight against cancer. 
There have been several instances of “incurable” patients going into remission after highly-experimen-
tal, last-resort gene therapies in the USA, UK, and China14, 16, 35, 42. In these cases, doctors harvested 
the patients’ immune cells and modified them with the ability to recognize and destroy cancer cells, 
making the treatment systemic, yet non-hereditary. 
Gene therapy is not widely used because the technology is still in its infancy. Most gene therapies 
have only reached clinical trials, though a handful of gene therapies have been approved for general 
use by the FDA15, 21, 22. Every nation has a unique set of rules defining what types of gene therapy are 
legal and under what conditions; generally, though, some type of somatic cell gene therapy is legal for 
clinical trials in most researching countries5, 37. Clinical trials have been conducted in 36 countries 
worldwide, and the USA accounts for more than half of them17. 
But synthetic biology gains most of its controversial undertones not from medical purposes, but 
from other theoretical applications, such as human cloning, embryo editing, and trait enhancement 
beyond normal levels. While creating a copy of someone doesn’t involve editing any genes, it does 
evoke many of the same controversial pictures as GE does. In theory, cloned human beings could be 
used to study disease, which was the purpose of cloning rhesus monkeys23, 25, 41. However, cloning or 
not, human experimentation without consent has exhaustive bans worldwide, including the United 
Nation’s International Covenant for Civil and Political Rights, which was enacted as law in 170 of the 
signing countries2, 20, 32. About 70 countries have explicitly banned human cloning, though some still 
allow cloning of non-viable human embryos for stem cell research8, 28. The United Nations also passed 
an ambiguous, non-binding agreement by split vote discouraging human cloning43. Thus, cloned hu-
man beings, while feasible, are a rare instance of international legislative cooperation and likely won’t 
be appearing anytime soon.
Obviously, technology is rapidly catching up to our wildest imaginations. For instance, it may 
soon be possible to genetically engineer a human in the womb. In 2015, Chinese scientists edited hu-
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man embryos in an attempt to cure a form of blood disease, 
though the embryos were intentionally non-viable7, 45. No one 
has ever attempted to genetically engineer a viable person in 
this fashion, but it’s theoretically possible to fix simple diseases 
like cystic fibrosis or sickle cell disease that are caused by a sin-
gle, well-studied genome mutation. In contrast to gene therapy, 
which is conducted in adults or children, changing the genes of 
an embryo would affect the resulting person’s entire body, and 
would be heritable by that person’s children, opening entirely 
new controversies and legislation30, 40. Today’s doctors avoid 
this practice in part because gene editing technologies such as 
CRISPR, homologous recombination, TALENs, and zinc fin-
gers are currently too error-prone for such medical uses. But 
their accuracy is rapidly improving4, 12, 24, 45.
The Chinese team’s study was received with international 
outcry from the scientific community, partly because of worries 
that their study could eventually lead to the enhancement of 
human traits for non-medical purposes7, 45. Many researchers 
warn against ever using gene editing for anything besides cur-
ing disease38, but sometimes curing a disease may accidentally 
lead to non-medical advantages30, as demonstrated when other 
Chinese researchers recently modified beagles to study Parkin-
son’s and muscular dystrophy: the gene they are targeting also 
causes both dogs and humans to become unnaturally strong18.
While it may soon be to enhance strength or cure muscular 
disorders, it is exceedingly more difficult to predict the future 
of enhancing or curing complex traits like height, intelligence, 
autism, mood disorders, or creativity. “Complex traits” are con-
trolled by many genes. For example, combined studies of over 
27,000 genomes have found 44 genetic factors that are correlat-
ed with height, yet estimate that 95% of the factors are still un-
discovered13. Similar studies estimate that intelligence could be 
controlled by hundreds or even thousands of different genes10, 
24, 45. Thus, the first problem with enhancing or fixing complex 
traits is finding the sheer number of genes that influence them6, 
13, 24, 45.
The second barrier, assuming all these genes are located, 
involves tradeoffs45: scientists postulate that a vast majority of 
genes affect multiple traits at once, often leading to both pos-
itives and negatives6. The same genes that increase height also 
correlate with shorter lifespans, and intelligence and creativity 
are correlated with conditions such as autism and emotional 
disorders like schizophrenia10, 36, 39. Trying to eliminate autism 
from the human population would eliminate many of society’s 
geniuses, just as erasing certain mood diseases such as bipolar 
disorder would likely reduce the number of great authors24. 
A third obstacle to modifying complex traits is deciding 
which traits to enhance and which to eliminate. Whereas edit-
ing complex traits may mean balancing positives and negatives, 
it may also mean deciding between two different positives. 
For example, there are different kinds of intelligence that are 
inversely correlated with each other: highly-detailed memory 
displays in individuals with deficient big-picture memory, and 
abnormally-high intelligence is often correlated with abnor-
mally-low creativity10. Some forms of mental capacity are mu-
tually exclusive. It might be easy for the world to decide that 
cancer is an objectively undesirable characteristic, but the pros 
and cons of some traits may be incredibly, if not entirely, sub-
jective24. This is not just a matter of individual opinion: to effec-
tively change such complicated traits, the edits would need to 
be made to an embryo, and not to a consenting adult. 
In summary, it is not currently possible to achieve our wild-
est dreams of curing complex diseases, nor can we achieve our 
wildest nightmares of superhuman enhancement: there are too 
many genes to find, and each gene may have both positive and 
negative effects. Even years in the future, enhancing or elimi-
nating complex traits may never be possible, because there is 
not an obvious definition of good or bad24. Many human traits 
have natural variability because different traits are “superior” in 
different situations24.
Taboos, ethical controversies, and a simple lack of technol-
ogy all contribute to the current lack of genetically-engineered 
humans, but some countries have also attempted to instate laws 
against GE in unborn humans7, 26, 38, 46. There are two types of 
GE: somatic cell editing and germline editing30. The germline 
includes reproductive cells such as sperm and eggs, which can 
be passed onto offspring40. Somatic cells make up the rest of 
the body and cannot be inherited40. Gene therapy is conducted 
on the somatic cells of consenting adults or children19, 27. But in 
order to change an entire human body, and not just a subset of 
tissues, the modifications would need to be made during early 
development in the womb, when a single injection could reach 
every cell in the forming embryo, affecting both somatic and 
germline cells30. Thus, countries differentiate between regula-
tions on somatic modifications like gene therapy, and the per-
manent germline modifications.
Laws forbidding germline editing for any purpose, be it 
medical or enhancement, have been enacted in Canada, Mexi-
co, Brazil, Australia, and most of western Europe. China, India, 
Japan, and Ireland have “guidelines” discouraging this, but they 
are not well-enforced and are subject to amendment or excep-
tion (hence China’s human germline edit in 2015)7, 26, 46. The 
rest of the major players, including Russia, South Africa, South 
American countries, Iceland, and the US, have unclear legis-
lation regarding germline editing26, 46. The United States gov-
ernment effectively brought GE embryonic research to a halt 
by imposing a temporary moratorium on government funding, 
and several states ban it by law11, 26, 31, 46. However, many states 
still allow private funding for such research31.
There are currently no binding international agreements on 
genetically engineering humans37, 46. Some scientists and NGOs 
have attempted to set some guidelines for future regulations, 
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calling for an international moratorium on funding for clin-
ical trials until more data is gathered from research30, 37.
This abundance of international confusion on the issue 
is concerning scientists worldwide. For if a country ever did 
decide to allow human engineering, there would be noth-
ing stopping those engineered humans from crossing in-
ternational borders. In 2016, an American couple wanted 
to conceive, but knew their kids would inherit the mother’s 
mitochondrial disease29. Scientists had recently developed 
a technique that would allow parents to conceive a child 
while using a healthy surrogate donor’s egg, thus replacing 
defective mitochondrial DNA and technically giving the 
child three parents29. The United States banned this tech-
nique due to its lack of precision, but the UK has already 
green-lighted the process, and Mexico does not enforce its 
restrictions on the technique3, 9, 29, 33. So the couple simply 
had the procedure done in Mexico, and their baby boy was 
born nine months later in New York9, 29. This illustrates the 
problem with different countries having different legisla-
tion: people move. If countries with lax legislation would 
allow some parents to cure their children of debilitating 
diseases, there is nothing stopping people from traveling in 
order to do so. And, once the modification is made, there is 
nothing stopping them from returning home.
The world must realize three things: firstly, that all 
countries are interconnected and must standardize their GE 
rules if they are going to be worth anything at all, because 
neither somatic nor germline editing respects national bor-
ders5, 27, 45.
Secondly, GE technology is not simply going to stop ad-
vancing, even if funding is cut, techniques are banned, and 
the public refuses to pay attention to it45. The desire to cure 
devastating diseases will always tempt desperate patients 
and parents worldwide45. Instead, whoever offers treatment 
to these desperate individuals will make the rules. Coun-
tries that fund research set the safety guidelines, gain over-
sight and control over procedures, and provide a safe envi-
ronment for patients to seek treatment. And only through 
research will the world be able to foresee the benefits and 
pitfalls of treatments.
Lastly, people need to stop treating these things as sci-
ence fiction meant only for Orphan Black, comic books, and 
Gattaca. Scientists and governments have so long ignored 
GE’s ethical implications because it was not yet possible, but 
science is rapidly breaking down barriers that previously 
seemed insurmountable40, 45. Some imagined GE techniques 
may never be possible, and others may completely blindside 
humanity, so when it comes to international agreement, it’s 
better that gene editing brings to mind an in-focus, univer-
sal picture, compared to the diverse collage we have now.
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